The Claim
In individuals with autosomal dominant Alzheimer’s disease, cerebrospinal fluid and plasma neurofilament light chain levels are strongly correlated during the presymptomatic phase (r² = 0.76), but the correlation between these biomarkers weakens significantly after symptom onset, indicating reduced reliability of plasma neurofilament light chain as a proxy for central nervous system neurodegeneration in symptomatic stages.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with inherited Alzheimer’s disease, levels of neurofilament light chain in spinal fluid and blood are closely linked before symptoms appear, but this link becomes much weaker after symptoms start, meaning blood levels are less accurate for tracking brain degeneration once the disease is active.
See the scientific wording
In autosomal dominant Alzheimer’s disease, neurofilament light chain levels in cerebrospinal fluid and plasma are strongly correlated during the presymptomatic phase (r² = 0.76), but this correlation weakens significantly after symptom onset, indicating that plasma NfL becomes a less reliable proxy for central nervous system neurodegeneration in symptomatic stages.
In early Alzheimer’s disease, damaged nerve cells release a protein called neurofilament light chain into the fluid around the brain, which then moves into the blood. As the disease progresses and symptoms appear, the flow of this protein from the brain into the blood slows down, so blood tests no longer reflect how much damage is happening in the brain.
What the research says
1 studyBefore symptoms appear, the level of a nerve damage marker in blood matches closely with the level in spinal fluid. But after symptoms start, the blood level stops rising while the spinal fluid level keeps going up — so blood tests become less accurate for tracking brain damage later on.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.